Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 4/20 | 0.62 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.57 |
| ▸ | KRAS | P01116 | 6/20 | 0.57 |
| ▸ | EIF4E | P06730 | 2/20 | 0.56 |
| ▸ | EIF4EBP1 | Q13541 | 2/20 | 0.56 |
| ▸ | BCL2A1 | Q16548 | 3/20 | 0.54 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.54 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10063472 | 0.89 | ESR1 (0.58) | ESR1ESR2KRASEIF4EEIF4EBP1 | |
| SCHEMBL17880430 | 0.68 | MDM2 (0.78) | ESR1KRASEIF4EEIF4EBP1BCL2A1 | |
| SCHEMBL30168007 | 0.68 | IL23R (0.49) | — | |
| SCHEMBL30168005 | 0.68 | IL23R (0.49) | — | |
| SCHEMBL19760420 | 0.68 | ESR1 (0.52) | ESR1ESR2KRASNFE2L2 | |
| SCHEMBL31157715 | 0.67 | SIRT5 (0.52) | — | |
| SCHEMBL17568826 | 0.66 | MDM2 (0.58) | ESR1ESR2KRASEIF4EEIF4EBP1 | |
| SCHEMBL18053128 | 0.66 | MDM2 (0.58) | ESR1ESR2KRASEIF4EEIF4EBP1 | |
| SCHEMBL17880428 | 0.65 | MAFG (0.53) | ESR1ESR2KRASNFE2L2 | |
| SCHEMBL26381272 | 0.65 | NFE2L2 (0.57) | ESR1KRASEIF4EEIF4EBP1NFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10022422-B2 | Peptidomimetic macrocycles | Alleron Therapeutics, Inc. (US) | 2018-07-17 | — | — | US | disclosed |
| US-20160250278-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2016-09-01 | — | — | US | disclosed |
| US-20160068573-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2016-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160250278-A1 | PEPTIDOMIMETIC MACROCYCLES | ZC3HAV1, HAVCR2, ZC3HAV1L | ESR1 2210/4885ESR2 2003/4885KRAS 1413/4885 |
| US-20160068573-A1 | PEPTIDOMIMETIC MACROCYCLES | ZC3HAV1, HAVCR2, ZC3HAV1L | ESR1 2210/4885ESR2 2003/4885KRAS 1413/4885 |
| US-10022422-B2 | Peptidomimetic macrocycles | HAVCR2, ZC3HAV1, ZC3HAV1L | ESR1 3362/4885ESR2 2581/4885KRAS 1271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.